Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders.
To evaluate the effect of 1-deamino-8-D-arginine vasopressin (DDAVP) in various bleeding disorders, 10 micrograms/m2 DDAVP was administered to subjects with von Willebrand disease (13), platelet function defects (12), von Willebrand disease and platelet defects together (8), or isolated prolongation of the bleeding time (5). DDAVP shortened the bleeding time similarly in all patient groups. Shortening of the bleeding time was also observed in 2 patients with aspirin-induced platelet defects and in 2 normal subjects. DDAVP administration was associated with falls in the platelet count, mean platelet volume, and partial thromboplastin time, and rises in platelet adhesion, factor VIII coagulant activity, factor VIII related antigen, and von Willebrand factor activity. The basal bleeding time was the only predictor of the magnitude of the bleeding-time correction. Normal haemostatis was achieved with DDAVP plus epsilon-aminocaproic acid and no blood product support during operations in 18 patients with bleeding disorders.
D000293:Adolescent; D000328:Adult; D015119:Aminocaproic Acid / Q000008:administration & dosage; D001127:Arginine Vasopressin / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001760:Bleeding Time; D001791:Blood Platelet Disorders / Q000097:blood*; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D004341:Drug Evaluation; D006487:Hemostasis / Q000187:drug effects; D006488:Hemostasis, Surgical; D006801:Humans; D010314:Partial Thromboplastin Time; D010973:Platelet Adhesiveness / Q000187:drug effects; D010976:Platelet Count; D010979:Platelet Function Tests; D014842:von Willebrand Diseases / Q000097:blood*
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin; D001241:Aspirin; D015119:Aminocaproic Acid